Published in:
01-08-2011 | Letter--Reply
Author reply
Authors:
Michael Grieco, Richard L. Whelan
Published in:
Surgical Endoscopy
|
Issue 8/2011
Login to get access
Excerpt
In their letter, Spiliotis and Zoras seem to misunderstand our position. It was never our belief that blood levels of epidermal growth factor (EGF) should be aggressively pursued as a clinical biomarker. The main purpose of our study “minimally invasive colorectal resection (MICR) associated with a rapid and sustained decrease in plasma levels of epidermal growth factor (EGF) in the colon cancer setting” was to determine the impact of MICR on postoperative plasma EGF levels in cancer patients. …